Patents Represented by Attorney, Agent or Law Firm Richard J. Mazza
  • Patent number: 6271364
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Ellen Ngoi Yin Cheung, Thomas Charles Boone, Susan Irene Hershenson, John David Young
  • Patent number: 6261820
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: July 17, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • Patent number: 6211150
    Abstract: The in vivo circulating life and/or absorption of the cationic therapeutic protein BDNF can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: April 3, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Patent number: 6197939
    Abstract: Polypeptide growth factors, termed PDPFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: March 6, 2001
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Patent number: 6080845
    Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear. A monoclonal antibody against adult rat utricular epithelium is also described.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: June 27, 2000
    Assignee: Amgen Inc.
    Inventor: Josette F. Carnahan
  • Patent number: 6075008
    Abstract: A method is disclosed which provides for the proliferation and growth of cells, such as prostate cells, by contacting them with an effective amount of a placental-derived prostate growth factor.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: June 13, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Patent number: 6025204
    Abstract: A diagnostic method is described for the detection of placental-derived growth factors which involves contacting a biological tissue or fluid sample with a labeled antibody which is specific to the growth factors and detecting the labeled reaction product.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 15, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Patent number: 6017886
    Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 25, 2000
    Assignee: Amgen Inc.
    Inventor: Josette F. Carnahan
  • Patent number: 5998170
    Abstract: Nucleic acid molecules are described which are useful in vectors, transformed or transfected host cells, and methods for the recombinant expression of hepatocyte growth-specific polypeptide members of the FGF family.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: December 7, 1999
    Assignee: Amgen Inc.
    Inventors: Tsutomu Arakawa, Dimitry Michael Danilenko, Nobuyuki Itoh, Francis Hall Martin
  • Patent number: 5929032
    Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Patent number: 5914251
    Abstract: Polypeptide growth factors, termed PDFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 22, 1999
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Patent number: 5874287
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Patent number: 5858977
    Abstract: A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes mellitus in mammals.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: January 12, 1999
    Assignee: Amgen Inc.
    Inventors: Sharon Lea Aukerman, Glenn Francis Pierce
  • Patent number: 5849705
    Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer
  • Patent number: 5830857
    Abstract: A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Antoine Depaulis, Paul Feltz, Yves Larmet, Christian Marescaux, Hiroyuki Nawa
  • Patent number: 5773600
    Abstract: The development of subunits and subunit analogs of the Bordetella exotoxin by recombinant DNA techniques provides vaccine products that retain their biological activity, are highly immunogenic, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits can result in products that retain immunogenicity, yet are free of enzymatic activity associated with toxin of reactogenicity.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 30, 1998
    Assignee: Amgen Inc.
    Inventor: Walter Neal Burnette, III
  • Patent number: 5770577
    Abstract: Derivatives of the neurotrophic factors BDNF and NT-3 have been prepared by attachment of these polypeptides to a water soluble polymer, for instance, polyethylene glycol.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 23, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf Boris Kinstler, Qiao Yan
  • Patent number: 5770203
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: June 23, 1998
    Assignees: Amgen Inc., University of Southern California
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Patent number: 5686415
    Abstract: Colon epithelial cells are stimulated to multiply, grow and mature by contacting them in vivo with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: November 11, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Patent number: 5670342
    Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 23, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga